Searchable abstracts of presentations at key conferences in endocrinology

ea0081p144 | Pituitary and Neuroendocrinology | ECE2022

Gene expression profiling of subcutaneous adipose tissue reveals new biomarkers in active acromegaly

Maria Falch Camilla , Arlien-Soborg Mai C. , Dal Jakob , Sundaram Arvind , Michelsen Annika E. , Ueland Thor , Olsen Linn G. , Heck Ansgar , Bollerslev Jens , Jorgensen Jens Otto , Olarescu Cristina

Objective: Patients with acromegaly present increased insulin resistance despite reduced adipose tissue (AT) mass. Growth hormone (GH) stimulates lipolysis, but the role of AT as a metabolic factor in patients with acromegaly is still uncertain. Moreover, there is a need for better biomarkers of disease activity in acromegaly.Methods: RNA-sequencing was performed on paired subcutaneous AT (SAT) biopsies from patients (n=6) with active acromegaly...

ea0049mte2 | (1) | ECE2017

Diagnosis and management of GH deficiency - from childhood to adulthood

Jorgensen Jens

Pituitary dwarfism has been known for many decades, originally as a component of organic panhypopituitarism. GH for clinical use was purified by Maurice Raben from human cadaveric pituitaries and tested for the first time and with success in 1957 in a patient with childhood onset disease. Moreover, pivotal short term studies on the metabolic effects were performed in both healthy and hypopituitary adults. The concomitant introduction of imunnoassays for GH led to the introduct...

ea0016s1.3 | The trick is the combination | ECE2008

Medical treatment of acromegaly: dual blockade with a somatostatin analog and Pegvisomant

Jorgensen Jens

Transsphenoidal surgery is preferred as primary therapy for acromegaly, but cure or acceptable disease control with this modality is obtained in <60%, and in some cases surgery is not eligible. Second-line treatment with long-acting somatostatin analogues (SA) is successful in ~60%. This treatment offers tumor shrinkage in addition to lowering of GH and IGF-I in most patients. A potential concern is impairment of glucose tolerance due to the concomitant suppression of insu...

ea0037ep70 | Adrenal cortex | ECE2015

Prevalence of hypercortisolism in type 2 diabetes patients: a meta-analysis

Steffensen Charlotte , Pereira Alberto , Dekkers Olaf M , Jorgensen Jens Otto

Background: Type 2 diabetes (T2D) and hypercortisolism associated with Cushing’s syndrome (CS) share clinical characteristics such as hypertension, dyslipidaemia, hyperglycaemia, and obesity. Several studies have recorded a relatively high prevalence of hypercortisolism in T2D, which may have therapeutic implications. The aim of this systematic review and meta-analysis was to assess the prevalence of hypercortisolism in T2D patients.Methods: Origina...

ea0099ep468 | Pituitary and Neuroendocrinology | ECE2024

Pasireotide as first line medical therapy for treatment of selected patients with acromegaly

Olarescu Nicoleta , Bollerslev Jens , Jorgensen Anders , Heck Ansgar

Objective: Pasireotide is a second-generation somatostatin receptor ligands (SRLs) with highest affinity for somatostatin receptor (SST)5, followed by SST2. It is considered, so far, in patients resistant to first-generation SRLs, after surgical failure. Histological characteristics and T2-weighted MRI can predict resistance to first-generation SRLs in patients with somatotroph adenomas. Previous studies primarily assessed efficacy of pasireotide as 2nd or 3rd line medical tre...

ea0090p412 | Pituitary and Neuroendocrinology | ECE2023

Copeptin levels increase in response to both insulin-induced hypoglycemia and arginine but not to clonidine – data from GH-stimulation tests

Stankovic Jelena , Kristensen Kurt , Birkebaek Niels , Otto Jorgensen Jens , Sondergaard Esben

Background: The differential diagnosis of the polyuria-polydipsia syndrome is challenging. The water-deprivation test is the current gold standard, but the test is cumbersome, and the diagnostic performance is poor. Copeptin, which is a split product of the vasopressin pre-propeptide, appears to be a robust biomarker in the circulation and a promising tool for the diagnosis of patients with polyuria and polydipsia, especially when measured in conjunction with intravenous infus...

ea0063p1109 | Pituitary and Neuroendocrinology 3 | ECE2019

HPA axis function in patients with clinically non-functioning pituitary adenomas: effects of surgery and risk factors for HPA failure

Kolnes Anders Jensen , Oystese Kristin Astrid , Dahlberg Daniel , Bollerslev Jens , Jorgensen Anders Palmstrom

Introduction: Patients planned for first time surgery for clinically non-functioning pituitary adenoma (NFPA) were included in this prospective study.Aims: – To study the prevalence of hypothalamic-pituitary-adrenal (HPA) axis failure preoperatively and 3 months after surgery for clinically NFPA.– To investigate factors predicting risk of HPA axis failure postoperatively.Hypotheses<p class="abst...

ea0049gp190 | Pituitary &amp; endocrine Tumours | ECE2017

Safety of long-term growth hormone (GH) treatment in adults with GH deficiency (GHD): an analysis from the NordiNet® International Outcome Study

Jorgensen Jens Otto , Popovic-Brkic Vera , Pournara Effie , Pedersen Birgitte , Chudecka Anita , Strasburger Christian

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

ea0049ep63 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment with modified-release hydrocortisone for 6 months: A clinical audit in 15 patients with adrenal insufficiency

Steffensen Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Kistorp Caroline , Jorgensen Jens Otto L

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

ea0049ep654 | Obesity | ECE2017

Growth hormone signaling and action in obese versus lean human subjects: evidence of increased hepatic GH sensitivity in obesity

Pedersen Morten Hogild , Bak Ann Mosegaard , Pedersen Steen Bonlokke , Jessen Niels , Moller Niels , Jorgensen Jens O.L.

Context: Obesity is accompanied by blunted GH secretion but relatively normal serum IGF-I levels, which suggests increased GH sensitivity. This, however, remains to be tested at the level of GH signaling in human subjects.Objective: To compare the effects of an acute intravenous GH bolus in obese vs normal weight subjects on GH signaling pathways in adipose and muscle tissue, substrate metabolism and insulin sensitivity.Subjects an...